Advanced searches left 3/3

Cancer Immunotherapy - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 10 June 2022

* If you want to update the article please login/register

Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials

"However, monotherapy with epi-u2010drugs or ICIs has demonstrated limited success in most cancer patients. " Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity in order to reduce immune evasion, but it has been noted that epigenetic drugs can even synergize with immunotherapy. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1002/cac2.12313


The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer

"The successful use of immunotherapy in advanced lung cancer has prompted researchers to investigate their clinical role as a neoadjuvant setting for resectable NSCLC and enhanced long-term survival and curative rates. " We discuss the attempts to include ICIs in the treatment strategy for surgically resectable lung cancer in this article. The earlyu2010phase findings from neoadjuvant clinical trials, the majority of active phase III trials, as well as the benefits of ICIs as a curative therapy for resectable lung cancer.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/cdt3.19


Survival after Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum‐based Chemotherapy for Locally Advanced (Stage III) Urothelial Cancer

"Despite treatment with cisplatin-u2010-based chemotherapy and surgical resection, clinical outcomes of patients with locally advanced urothelial carcinoma remain poor. " We compared neoadjuvant/induction platinum-u2010-based combination chemotherapy with combined immune checkpoint inhibition in combination. We discovered 602 patients who attended our outpatient bladder cancer clinic in 2018 u201019. U20103M0 UC 1 UC if you were a student with a registered NAIC or CI for cT3 or cICI in aN0M0 or cT1M0. In the case of cisplatinu2010ineligibility, the NAIC was composed of cisplatinu2010based chemotherapy or gemcitabine u2010carboplatinu2010carboplatin. In the NABUCCOu2010trial trial, a subgroup of patients received ipilimumab plus nivolumab. 107 stage III UC patients were treated with NAIC or cICI, according to us. We had 107 patients treated with NAIC or cICI. In 11 NAIC u2010patients and 11 cICIu2010patients, complete pathological response was obtained after resection. Our analysis revealed improved results in stage III UC patients treated with cici, compared to NAIC. In a comparative phase u20103 trial, our findings provide a solid basis for the validation of cICI for locally advanced UC.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/ijc.34125


Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy

"Cancer immunotherapy has significantly improved the treatment paradigm in oncology," with approvals of immunoglobulin immunotherapy drugs for over 16 indications, many of which were first line. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1111/cts.13312


A tumor metastasis‐associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity

"Abstract" is the short version of "Abstract" suggests that although neoantigens are one of the most useful in cancer immunotherapy, applying neoantigen vaccines to patients is difficult and costly due to individual differences. Immunogenic tumor cells cannot survive in the early stages of tumor progression, which includes two processes: elimination and equilibrium, according to the cancer immunoediting method. After an immune suppressive tumor microenvironment was established, we hypothesized that high immunogenic molecules were able to be expressed in tumor cells, prompting tumor cell formation, if these molecules are responsible for tumor formation. TWIST1 had an immunogenic peptide sequence TWIST1140+Tu2010cells, which subsequently stimulated TWIST1u2010specific CD4+ Tu2010cells, according to We demonstrated that TWIST1 had an immunogenic peptide sequence TWIST1140–u2013162, which in effect activated TWIST1u2010specific TWIST1–u2010 cells. "TWIST1-reactive HTLs in humanized mice were also increased by effective vaccination with the TWIST1 peptide. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1111/cas.15429


Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy

Following the PDCD1/CD247 checkpoint inhibitor, the CD47/SIRP1 target has become another common tumor immunotherapy target. A large number of CD47/SIRP/u03b1 mAbs, fusion proteins, and CD47/SIRP-u2013-b1-based bispecific antibodies have been performing preclinical and clinical trials in the treatment of hematologic tumors and solid tumors in recent years. We explore the development of CD47-based BsAb molecules with a different target, analyze the safety and efficiency of preclinical and clinical trials, explore the challenges that may be faced in the production of CD47+ BsAbs, and dual target molecules, along with their progress estimates. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1111/imm.13498


Targeted Cancer Immunotherapy by Nanoparticle T Cell Engagers

"The most common form of leukemia is acute myeloid leukemia. " Emerging immunotherapies such as chimeric antigen receptor T cells and T cell engagers have the ability to enhance T cell recognition and response to cancer, but come with significant limitations such as short life, complicated manufacturing, high cost, and inability to develop for another antigen. We previously developed a nanoparticle-based T cell engagers system that has a longer lifespan than u2010, is easy to make, is highly customizable, and robustly activates T cells for cancer killing. We hypothesized that nanoTCEs targeting CD33/CD3 will effectively boost T cell proliferation in an AML disease model in this study. For 2 hours, fluorescently labeled nanoTCEs were used to adhere human T cells and AML cell lines. After four days in a 3D culture system, flow cytometry confirmed the activation of T cell subsets and killing of AML cell lines. Results The results of AML cell lines had a higher frequency of CD33 in comparison to controls. NanoTCEs bound to human T cells and AML cell lines with greater specificity than isotype controls are bound to human T cells and AML cell lines with increased sensitivity and AML cell lines with greater sensitivity than isotype controls. In addition, our in vivo findings showed that weekly CD33/CD3 nanoTCE injections extended survival and reduced tumor formation in AML bearing mice compared to Isotype/CD3 nanoTCE treated mice. T cells were specifically linked to AML cells, which prompted T cell proliferation and AML cell destruction both in vitro and in vivo.

Source link: https://onlinelibrary.wiley.com/doi/10.1096/fasebj.2022.36.S1.R2489

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions